A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine

A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine

Over 95% of Pancreatic ductal adenocarcinomas (PDA) carry mutations in the oncogene KRas which has been proven to be a difficult drug target. P21-activated kinase 4 (PAK4), acts downstream of KRas, and is overexpressed in PDA contributing to its growth and chemoresistance, and thus becomes an attrac...

Full description

Bibliographic Details
Main Authors: Hong He, Chelsea Dumesny, Ching-Seng Ang, Li Dong, Yi Ma, Jun Zeng, Mehrdad Nikfarjam
Format: Article
Language:English
Published: Elsevier 2022-02-01
Series:Translational Oncology
Subjects:
Pancreatic cancer
PAK4
KRas
Gemcitabine
Online Access:http://www.sciencedirect.com/science/article/pii/S193652332100320X

Similar Items

Similar Items